Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer

Status Not yet recruiting

Clinical Trial Summary

Gastric cancer is the second cause of cancer related death and China has the most gastric cancer patients in the world. Although systemic strategies, including adjuvant chemotherapy, postoperative chemoradiotherapy, perioperative chemotherapy, have evolved and showed benefits these years, the prognosis of advanced gastric cancer is still not satisfactory. Optimal regimens and optimal method administration is still being found. Neoadjuvant chemotherapy has many advantages, including downstaging the tumor, increasing R0 rate, early eradicating of micrometastasis. In previous trials, combination of paclitaxel and s-1 has showed safety and tolerance in recurrent or metastatic gastric cancer. Using liposome as a carrier, paclitaxel has a better histocompatibility and cellular affinity, resulting a improved stability and reduced toxicity. In this phase II trial, we are going to study the safety and feasibility of paclitaxel liposome plus s-1 as neoadjuvant chemotherapy.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02163291
Study type	Interventional
Source	Peking University
Contact	Jiafu Ji, M.D.
Email	jiafuj@hotmail.com
Status	Not yet recruiting
Phase	Phase 2
Start date	December 2013
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05545293` - Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers
Recruiting	`NCT05620732` - Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T	N/A
Recruiting	`NCT05221775` - Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients	Phase 1
Completed	`NCT05334849` - Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Not yet recruiting	`NCT05313906` - RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer	Phase 2
Completed	`NCT00192088` - A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma	Phase 2
Terminated	`NCT04718402` - A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma	Phase 1
Active, not recruiting	`NCT01534546` - Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection	Phase 3
Recruiting	`NCT04739202` - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)	Phase 2
Not yet recruiting	`NCT05270824` - Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma	Phase 3
Completed	`NCT05997524` - Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.	Phase 2
Recruiting	`NCT06264921` - A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05805956` - IMM2902 in Patients With Advanced Solid Tumors Expressing HER2	Phase 1/Phase 2
Recruiting	`NCT04704661` - Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Phase 1
Not yet recruiting	`NCT04808791` - A Phase II Trial of iTTo in Advanced Gastric and GEJ Adenocarcinoma	Phase 2
Recruiting	`NCT06028737` - Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT04491942` - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	Phase 1
Recruiting	`NCT05969860` - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer	Phase 2
Active, not recruiting	`NCT04535401` - Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	Phase 1
Recruiting	`NCT05226169` - Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)	Phase 3